2 Biotech Stocks Worth Buying Before Their Potential Buyouts

▤ Summary

This piece highlights two biotech companies, Legend Biotech and BioNTech, as potential takeover targets in a busy pharma M&A market. It points to Legend Biotech’s commercial CAR-T therapy Carvykti and its manufacturing capabilities as major acquisition assets. It also emphasizes BioNTech’s large cash position, late-stage oncology pipeline, and upcoming clinical readouts as factors that could attract buyers. The article frames both companies as possible buyout candidates rather than reporting an actual transaction.

▦ Linked Companies